Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

January 25, 2010

mondoBIOTECH holding AG: the Board of Directors has set the final terms of its planned capital increase

NOT FOR DISTRIBUTION IN THE UNITED STATES (OR TO US CITIZENS), THE UNITED KINGDOM AND THE EEA. mondoBIOTECH holding AG: the Board of Directors has set the final terms of its planned capital increase Stans, Switzerland - January 25, 2010. mondoBIOTECH holding AG announces today the final terms of  its planned capital increase (the "Offering"). Holders of every 215 subscription rights will be offered one new common share and one option entitling its holder to subscribe within an exercise period of 3 years for one new common share, for a global amount of CHF 150.00, being CHF 110.00 the subscription price for one offered common share and CHF 40.00 the purchase price for one option (the "Option Price"). The option will have a strike price of CHF 150.00. Assuming subscription of all new shares and options offered, the net proceeds from the Offering will amount to approximately CHF 43 million. The newly raised funds will be used to finance the further development of the Company’s product pipeline and therefore contribute to speed-up the process of making further medicinal product candidates available on the market. Mondobiotech's share closed at CHF 211.00 on Friday 22 January 2010. As communicated on 14 January 2010, the capital increase will be conducted by way of a rights offering to existing shareholders. The Company's share capital will be increased out of authorized share capital by issuance of up to 304’131 fully paid-in registered common shares with a par value of CHF 0.10 each. Under the terms of the Offering, existing shareholders will be allotted 10 tradable subscription rights for each listed common share and 1 subscription right for each non-listed voting right share held after close of trading on the SIX Swiss Exchange on 25 January 2010. 215 subscription rights entitle to subscribe for one new common share at the subscription price of CHF 110.00. Accordingly, 43 existing common shares entitle to two new common shares and 215 voting right shares entitle to one new common share. In addition, every 215 subscription rights exercised to subscribe for new common shares give the respective subscriber the opportunity to purchase one option  at the Option Price of CHF 40.00 (i.e. subscription for one new common share entitles to purchase one option). An option entitles its holder to subscribe within an exercise period of 3 years (starting 22 February 2010 and ending 22 February 2013, 12:00 noon CET) for one new common share. The strike price per option is CHF 150.00. The subscription rights will be traded on the SIX Swiss Exchange from 26 January 2010 until on or about 9 February 2010 (ticker symbol: RARE1). Ex-rights trading in the existing common shares will begin on 26 January 2010. The exercise period for the subscription rights will run from 26 January 2010 until on or about 16 February 2010, 12:00 noon (CET). The first trading day of the new common shares on the SIX Swiss Exchange is expected to be 19 February 2010 (ticker symbol: RARE). The new common shares will be fully fungible with the existing common shares. The options may be transferred, but will not be listed for the time being. The major shareholders of the Company, holding an aggregate of 73% of the voting rights in the Company, have decided to assign their subscription rights to Imperial Fund Ltd., one of the largest shareholders holding common shares of the Company, free of charge as an appreciation for Imperial Fund's great support to the Company in the past and the present. Imperial Fund Ltd. has committed to exercise or cause other investors to exercise all of the subscription rights allotted and assigned to it in the Offering and to subscribe or cause such investors to subscribe for the corresponding number of new common shares. Accordingly, at least 65% of the common shares offered are expected to be placed with Imperial Fund Ltd. and/or investors referred by it. The offered shares will not be underwritten. Accordingly, the exact number of common shares and options to be issued depends on the total amount of subscriptions received from existing shareholders and/or acquirors of subscription rights in the Offering. About Mondobiotech mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. For further information please contact: Dr. Yvonne Gunsch-Wegmann, MBA Head of External Relations mondoBIOTECH holding AG Das Kloster Mürgstrasse 18 CH-6370 - Stans - Switzerland T   +41 (0)840 200 010 F   +41 (0)41 611 09 34 M  +41 (0)79 414 39 33 investor@mondobiotech.com www.mondobiotech.com Disclaimer The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. Mondobiotech Holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. ANY NON-COMPLIANCE WITH SUCH RESTRICTIONS MAY RESULT IN AN INFRINGEMENT OF U.S. SECURITIES LAWS. SECURITIES OF MONDOBIOTECH HOLDING AG ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF MONDOBIOTECH HOLDING AG HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT THE REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES LAWS. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR ART. 27 ET SEQ. OF THE SIX LISTING RULES. This document is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this information or any of its contents. Personal Information This email is from MondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your system. Download the Newsletter in pdf format

Back to list